Niacinamide (vitamin B3) enhanced the ability of LL-37 — the human body's own antimicrobial peptide — to neutralize multiple SARS-CoV-2 variants by disrupting the viral membrane.
Inverse correlation with severityCOVID-19 patients with higher LL-37 levels had less severe disease, suggesting the peptide plays a protective role during infection
What the researchers found
Human cathelicidin LL-37 neutralized multiple SARS-CoV-2 variants through direct disruption of the viral membrane, as confirmed by biophysical and computational studies. Niacinamide enhanced this antiviral activity through its hydrotropic action, which may increase the bioavailability of LL-37.
Clinically, an inverse correlation was observed between LL-37 levels and COVID-19 disease severity in patients — those with higher LL-37 levels had milder disease. The combination of niacinamide and LL-37 showed potent antiviral activity against various SARS-CoV-2 variants, including those that escape vaccine-generated immunity.
Why it matters
As SARS-CoV-2 continues to evolve and potentially escape vaccine immunity, strategies that harness the body's innate defenses offer a variant-agnostic approach. LL-37 targets the viral membrane itself — a structural feature shared across all variants — rather than the spike protein that vaccines target and that mutates frequently. Niacinamide is a cheap, widely available vitamin, making this combination potentially accessible worldwide.
How the study worked
The study combined multiple approaches: biophysical experiments to test LL-37's ability to disrupt SARS-CoV-2 membranes, computational modeling to understand the mechanism of interaction, clinical correlation analysis of LL-37 levels versus COVID-19 severity in patients, and testing of niacinamide's ability to enhance LL-37's antiviral activity across multiple viral variants.
What this study cannot tell us
The primary findings are laboratory-based (in vitro and computational), not from a clinical trial testing niacinamide + LL-37 as a treatment. The clinical correlation between LL-37 levels and disease severity is observational and cannot prove causation. The study does not demonstrate that taking niacinamide supplements would raise LL-37 levels enough to provide clinical protection. The mechanism by which niacinamide increases LL-37 bioavailability needs further characterization.
How to read the evidence
This is primarily a laboratory and computational study with supportive clinical correlation data. While the mechanistic evidence is compelling, no controlled clinical trial of the niacinamide + LL-37 combination was conducted. Evidence strength is low to moderate for clinical applicability.
When this study was published
Published in 2023 in Frontiers in Immunology, this is a recent study from the later phase of COVID-19 research when attention had shifted toward variant-resistant strategies and innate immunity.
The bigger picture
This study connects two important threads: the growing recognition that antimicrobial peptides are critical first responders against viral infections, and the search for broadly effective COVID-19 countermeasures that work regardless of variant. It also adds to evidence that nutritional status (in this case, vitamin B3) can influence innate immune defense through peptide pathways — a concept relevant far beyond COVID-19.
Questions still open
- Would oral niacinamide supplementation raise LL-37 levels enough in the respiratory tract to provide meaningful antiviral protection?
- Could a topical nasal formulation of LL-37 plus niacinamide prevent SARS-CoV-2 infection at the point of entry?
- Does the inverse correlation between LL-37 and COVID severity reflect causation, or are sicker patients simply depleting their LL-37 faster?
Common questions
What is LL-37 and how does it fight viruses?
Should I take niacinamide to protect against COVID-19?
Read the original research
Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption.
Frontiers in immunology, 14, 1255478
Citation
Bhatt, Tanay; Dam, Binita; Khedkar, Sneha Uday; Lall, Sahil; Pandey, Subhashini; Kataria, Sunny; Ajnabi, Johan; Gulzar, Shah-E-Jahan; Dias, Paul M; Waskar, Morris; Raut, Janhavi; Sundaramurthy, Varadharajan; Vemula, Praveen Kumar; Ghatlia, Naresh; Majumdar, Amitabha; Jamora, Colin. (2023). Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption.. Frontiers in immunology, 14, 1255478. https://doi.org/10.3389/fimmu.2023.1255478